Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMuiño, Elena
dc.contributor.authorMaisterra Santos, Olga
dc.contributor.authorJimenez Balado, Joan
dc.contributor.authorCullell, Natalia
dc.contributor.authorCarrera, Caty
dc.contributor.authorTorres‑Aguila, Nuria P.
dc.date.accessioned2021-11-15T11:45:03Z
dc.date.available2021-11-15T11:45:03Z
dc.date.issued2021-03-25
dc.identifier.citationMuiño E, Maisterra O, Jiménez-Balado J, Cullell N, Carrera C, Torres-Aguila NP, et al. Genome-wide transcriptome study in skin biopsies reveals an association of E2F4 with cadasil and cognitive impairment. Sci Rep. 2021 Mar 25;11:6846.
dc.identifier.issn2045-2322
dc.identifier.urihttp://hdl.handle.net/11351/6545
dc.descriptionDementia; Headache; Stroke
dc.description.abstractCADASIL is a small vessel disease caused by mutations in NOTCH3 that lead to an odd number of cysteines in the EGF-like repeat domain, causing protein misfolding and aggregation. The main symptoms are migraine, psychiatric disturbances, recurrent strokes and dementia, being executive function characteristically impaired. The molecular pathways altered by this receptor aggregation need to be studied further. A genome-wide transcriptome study (four cases paired with three healthy siblings) was carried out, in addition to a qRT-PCR for validation purposes (ten new cases and eight new controls). To study the expression profile by cell type of the significant mRNAs found, we performed an in situ hybridization (ISH) (nine cases and eight controls) and a research in the Single-nuclei Brain RNA-seq expression browser (SNBREB). Pathway analysis enrichment was carried out with Gene Ontology and Reactome. Neuropsychological tests were performed in five of the qRT-PCR cases. The two most significant differentially expressed mRNAs (BANP, p-value = 7.23 × 10–4 and PDCD6IP, p-value = 8.36 × 10–4) were selected for the validation study by qRT-PCR. Additionally, we selected two more mRNAs (CAMK2G, p-value = 4.52 × 10–3 and E2F4, p-value = 4.77 × 10–3) due to their association with ischemic neuronal death. E2F4 showed differential expression in the genome-wide transcriptome study and in the qRT-PCR (p = 1.23 × 10–3), and it was upregulated in CADASIL cases. Furthermore, higher E2F4 expression was associated with worse executive function (p = 2.04 × 10–2) and attention and information processing speed (IPS) (p = 8.73 × 10–2). In situ hibridization showed E2F4 expression in endothelial and vascular smooth vessel cells. In silico studies indicated that E2F4 is also expressed in brain endothelial cells. Among the most significant pathways analyzed, there was an enrichment of vascular development, cell adhesion and vesicular machinery terms and autophagy process. E2F4 is more highly expressed in the skin biopsy of CADASIL patients compared to controls, and its expression is present in endothelial cells and VSMCs. Further studies are needed to understand whether E2F4 could be useful as a biomarker, to monitor the disease or be used as a therapeutic target.
dc.language.isoeng
dc.publisherNature Research
dc.relation.ispartofseriesScientific Reports;11
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectTrastorns de la cognició
dc.subjectTranscriptomes
dc.subject.meshTranscriptome
dc.subject.meshCognitive Dysfunction
dc.subject.mesh/pathology
dc.titleGenome-wide transcriptome study in skin biopsies reveals an association of E2F4 with cadasil and cognitive impairment
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1038/s41598-021-86349-1
dc.subject.decstranscriptoma
dc.subject.decsdisfunción cognitiva
dc.subject.decs/patología
dc.relation.publishversionhttps://doi.org/10.1038/s41598-021-86349-1
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Muiño E, Carrera C, Torres-Aguila NP] Stroke Pharmacogenomics and Genetics Group, Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [Maisterra O, Jiménez-Balado J] Laboratori de Recerca Neurovascular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Cullell N] Stroke Pharmacogenomics and Genetics Group, Institut de Recerca de l`Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Stroke Pharmacogenomics and Genetics, Fundació MútuaTerrassa per la Docència i la Recerca, Terrassa, Spain
dc.identifier.pmid33767277
dc.identifier.wos000635699600007
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/CM18%2F00198
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record